1. Tejera-Muñoz, Antonio, Cortés, Marcelino, Rodriguez-Rodriguez, Alianet, Ruiz-Ortega, Marta, Rodrigues-Díez, Raul R. 2024. Ccn2 Deletion Reduces Cardiac Dysfunction, Oxidative Markers, and Fibrosis Induced by Doxorubicin Administration in Mice. In International journal of molecular sciences, 25, . doi:10.3390/ijms25179617. https://pubmed.ncbi.nlm.nih.gov/39273564/
2. Li, Shanshan, Shao, Rui, Li, Shufa, Zou, Weiguo, Zhang, Zhenlin. 2024. A monoallelic variant in CCN2 causes an autosomal dominant spondyloepimetaphyseal dysplasia with low bone mass. In Bone research, 12, 60. doi:10.1038/s41413-024-00364-2. https://pubmed.ncbi.nlm.nih.gov/39414788/
3. Yang, Jiayi, Zhuang, Hongjie, Li, Jinhua, Nikolic-Paterson, David J, Yu, Xueqing. 2024. The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism. In The Journal of clinical investigation, 134, . doi:10.1172/JCI178392. https://pubmed.ncbi.nlm.nih.gov/38625739/
4. Qiu, Youjing, Tang, Jia, Saito, Takashi. 2018. The in vitro effects of CCN2 on odontoblast-like cells. In Archives of oral biology, 94, 54-61. doi:10.1016/j.archoralbio.2018.06.017. https://pubmed.ncbi.nlm.nih.gov/30168419/
5. Rayego-Mateos, Sandra, Morgado-Pascual, José Luis, Lavoz, Carolina, Marchant, Vanessa, Ruiz-Ortega, Marta. 2022. CCN2 Binds to Tubular Epithelial Cells in the Kidney. In Biomolecules, 12, . doi:10.3390/biom12020252. https://pubmed.ncbi.nlm.nih.gov/35204752/